Search Results - Michelle Xia

Michelle Xia

Michelle Xia (born 1966 or 1967) is a Chinese billionaire businesswoman, and the founder, CEO, chairwoman and president of the pharmaceutical startup Akeso Biopharma.

Xia was raised in Gansu province, the daughter of two university-educated engineers.

She earned a degree in biochemistry from Sun Yat-sen University in Guangzhou in 1988, and a doctorate in molecular biology and microbiology from Newcastle University in the UK.

Under Xia, Akeso have developed Ivonescimab, which appears to outperform Pembrolizumab (marketed as Keytruda), produced by Merck in the US.

In March 2025, she was included in the Time100 Health 2025.

As of July 2025, ''Forbes'' estimates her net worth at US$1.2 billion. Provided by Wikipedia
  • Showing 1 - 4 results of 4
Refine Results
  1. 1
    Cover Image

    Cadonilimab, a tetravalent PD-1/CTLA-4 bispecific antibody with trans-binding and enhanced target binding avidity by Xinghua Pang, Zhaoliang Huang, Tingting Zhong, Peng Zhang, Zhongmin Maxwell Wang, Michelle Xia, Baiyong Li

    Published 2023
    Connect to this object online.
    Book

    Save to List
    Saved in:
  2. 2
    Cover Image

    Safety, Pharmacokinetics and Preliminary Efficacy of IL4-Rα Monoclonal Antibody AK120 in Both Healthy and Atopic Dermatitis Subjects: A Phase I, Randomized, Two-Part, Double-Blind,... by Christopher John Wynne, Alexandra Cole, Charlotte Lemech, Guoqin Wang, Yu Zhang, Benchao Chen, Max Wang, Baiyong Li, Michelle Xia, Rodney Sinclair

    Published 2023
    Connect to this object online.
    Book

    Save to List
    Saved in:
  3. 3
    Cover Image

    Population pharmacokinetic/pharmacodynamic analysis of AK111, an IL-17A monoclonal antibody, in subjects with moderate-to-severe plaque psoriasis by Qian Li, Ju Qiao, Hongzhong Jin, Benchao Chen, Zhimei He, Guoqin Wang, Xiang Ni, Max Wang, Michelle Xia, Baiyong Li, Rui Chen, Pei Hu

    Published 2022
    Connect to this object online.
    Book

    Save to List
    Saved in:
  4. 4
    Cover Image

    Ebronucimab in Chinese patients with hypercholesterolemia---A randomized double-blind placebo-controlled phase 3 trial to evaluate the efficacy and safety of ebronucimab by Yanyan Zhang, Zhaohui Pei, Beijian Chen, Yanling Qu, Xiaolin Dong, Binge Yu, Guoqin Wang, Fang Xu, Dongmei Lu, Zhimei He, Benchao Chen, Lei Ma, Max Wang, Baiyong Li, Michelle Xia, Bo Zheng, Yong Huo

    Published 2024
    Connect to this object online.
    Book

    Save to List
    Saved in:

Search Tools: